cns-2022-0005 Suppl.pdf (96.56 kB)
Download fileSupplementary Tables 1 and 2. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.
dataset
posted on 2022-05-16, 10:12 authored by John de Groot, Martina Ott, Jun Wei, Cynthia Kassab, Dexing Fang, Hinda Najem, Barbara O’Brien, Shiao-Pei Weathers, Nazanin K Majd, Rebecca A Harrison, Gregory N. Fuller, Jason T. Huse, James P. Long, Raymond Sawaya, Ganesh Rao, Tobey J. MacDonald, Waldemar Priebe, Michael DeCuypere, Amy B. HeimbergerSupplementary Table 1.
Supplementary Table 2: PK Modeling Summary of WP1066 in Human Plasma